| Primary information |
|---|
| sequence ID | Seq_5625 |
| Peptide sequence | NGFKSHALQLNNR |
| CancerPDF_ID | CancerPDF_ID35, CancerPDF_ID906, CancerPDF_ID1050, CancerPDF_ID1900, CancerPDF_ID3162, CancerPDF_ID8558, CancerPDF_ID9469, CancerPDF_ID9616, |
| PMID | 16896061,19795908,16395409,21136997,21136997,23667664,26379225,21533267 |
| Protein Name | Complement C4 precursor,Complement C4-B,Complement C4 precursor,Complement C4-B,Complement C4-A,Complement C3f,Complement C4-A/Complement C4-B,Complement C4-A |
| UniprotKB Entry Name | "CO4A_HUMAN,CO4B_HUMAN",CO4B_HUMAN,CO4A_HUMAN,CO4B_HUMAN,CO4A_HUMAN,CO3_HUMAN,"CO4A_HUMAN,CO4B_HUMAN",CO4A_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Plasma,Serum,Plasma,Serum |
| M/Z | 1498.91,749.89,1498.91,1497.78006,1497.7801,1497.78,1499.79,500.27 |
| Charge | 1,2,1,1,1,1,NA,3 |
| Mass (in Da) | 1498.78,NA,NA,NA,NA,1499.67,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,MALDI-TOF,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,MALDI-TOF/TOF,LC/MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,NA,NA,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,NA,NA,NA,NA,1.49 |
| CancerPDF_ID | CancerPDF_ID35, CancerPDF_ID906, CancerPDF_ID1050, CancerPDF_ID1900, CancerPDF_ID3162, CancerPDF_ID8558, CancerPDF_ID9469, CancerPDF_ID9616, |
| p-Value | 1.00E-05,NA,5.31E-15,NA,NA,NA,NA,NA |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT (v 2.3),MASCOT |
| Length | 13,13,13,13,13,13,13,13 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,"Breast cancer, Lung cancer, Rectal cancer",Colorectal cancer,Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,UniprotKB,Swissprot Database (57.4) |
| Modification | NA,NA,NA,NA,NA,NA,Deammidated ,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy","94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative",62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 809 and 1 in prostate, bladder and breast cancer respectively",NA,NA,NA,Lower intensity in liver metastasis group than adenoma and CRC groups,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,NA,NA,MRM-based validation of 19 candidates |
| Sensitivity | 95% on independent dataset,NA,97.5% on independent validation dataset,NA,NA,NA,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,97.5 % on validation dataset,NA,NA,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |